Takeda reveals PhII fail for rare genetic condition, looks to new product pipeline to bolster growth
Takeda’s Phase II program in a rare hereditary disease called metachromatic leukodystrophy (MLD) is “likely to be discontinued” after failing its primary and secondary endpoints, the company revealed Thursday in its latest quarterly earnings report.
MLD is a fast-progressing and fatal neurodegenerative condition that can affect patients’ movement, speech, ability to walk, and even behavior. It’s commonly diagnosed in childhood, and caused by the deficiency of an enzyme called arylsulfatase A. Takeda’s candidate, TAK-611, is an enzyme replacement therapy that makes use of technology licensed from BioMarin. However, the company noted Thursday that the candidate “did not meet primary and secondary endpoints” in a Phase II study.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.